Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, 'Play It Forward,' to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS is a rare kidney disease (RKD) affecting children and adults and a leading cause of kidney failure.
"We are proud to support the FSGS community in amplifying individual expressions of life and courage, and we're committed to transforming the challenges of FSGS into pathways of hope and healing."
Share
Launching on the first-ever FSGS Awareness Day, the campaign features a powerful anthem, written and produced by Grammy-winning musician Brian Kennedy and singer-songwriter, David Rush, both living with FSGS. The song celebrates the strength of the FSGS community coming together. The musicians invite the FSGS community to use the soundtrack to post their own creative and artistic expressions on social media, showcasing the unique talents of the community and the stories of individuals who are thriving beyond the limits of FSGS.
"When I received my FSGS diagnosis, it felt like the volume of my life was suddenly turned down. My studio became my sanctuary," said Brian Kennedy, a multi-Grammy-winning producer, songwriter, and pianist. "I'm proud to play it forward with music that helps others hear their own strength. Together, we're translating the invisible struggle of FSGS into creative expressions that everyone can witness, creating a soundtrack for solidarity."
"Every FSGS story has the power to make a meaningful difference in someone else's life," said David Rush, singer, songwriter, motivational speaker, FSGS advocate, and patient. "While living with FSGS may try to dim my light, my music replenishes my spirit – that's how I play it forward for others fighting FSGS. This campaign provides a platform for patients and their loved ones to share experiences that offer hope, guidance, and inspiration to others facing similar challenges."
The campaign launch also features a hero video featuring Kennedy and Rush discussing their FSGS journeys and documenting the creation of their anthem. By uniting with the FSGS community, the two artists turn isolation into connection, using their shared experiences to inspire and empower others living with FSGS.
"On FSGS Awareness Day and every day, we know that obstacles impede every step of the patient journey -- from diagnostic hurdles to an often-aggressive progression to kidney failure,' said Jula Inrig, M.D., chief medical officer at Travere Therapeutics. 'We are proud to support the FSGS community in amplifying individual expressions of life and courage, and we're committed to transforming the challenges of FSGS into pathways of hope and healing."
To follow or participate in the campaign, search #PlayitForwardFSGS. Learn more at RKDandMe.com/PlayItForwardFSGS.
About FSGS
Focal segmental glomerulosclerosis (FSGS) is a rare proteinuric kidney disorder in children and adults that is estimated to affect more than 40,000 patients in the U.S., with similar prevalence in Europe. The disorder is defined by progressive scarring of the kidneys and often leads to kidney failure. FSGS is characterized by proteinuria, in which protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. Once in the urine, protein is toxic to other parts of the kidney, especially the tubules, and is believed to contribute to further disease progression. Other common symptoms include swelling in parts of the body, known as edema, as well as low blood albumin levels, abnormal lipid profiles and hypertension. There are currently no FDA-approved pharmacologic therapies for FSGS.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Elle
an hour ago
- Elle
Finished 'Dept. Q'? Netflix's New Murder Mystery 'The Survivors' Should Be Your Next Watch
For those looking to fill the Dept. Q-shaped whodunnit hole in their life, Netflix has come up trumps, once again, with yet another murder mystery: The Survivors. The Survivors, which launched on the platform on June 6, stars Charlie Vickers as Kieran Elliott and Bridgerton's newest darling Yerin Ha as Mia Chang, a young couple who are haunted by ghosts of their past when they return to their childhood hometown to be with Kieran's ailing father and emotionally distant mother, per Netflix. FIND OUT MORE ON ELLE COLLECTIVE The limited six-episode series, which is based on the bestselling Jane Harper novel of the same name, boasts all of the elements of a winning murder mystery with a brooding, simmering tension throughout and a moody, murderous setting, not dissimilar from its Dept. Q predecessor. Needless to say, it's the murder mystery we all ought to be bookmarking and binging. This is everything you need to know about The Survivors. Set in the fittingly sleepy seaside town Evelyn Bay in Tasmania, The Survivors tells the story of Kieran (Vickers) and Mia (Ha) as they return to their emotionally fraught hometown. 'Kieran Elliott's life changed forever when two people drowned and a young girl went missing in his hometown of Evelyn Bay,' per Netflix. 'Fifteen years later, returning with his young family, the guilt that still haunts him resurfaces. When the body of a young woman is found on the beach, the town is once again rocked by tragedy and the investigation of her death threatens to reveal long-held secrets, the truth about the missing girl, and a killer among them.' 'It's a family melodrama disguised as a murder mystery,' the series' showrunner Tony Ayres said of the series. 'Because the things that are really at its heart are things like a son wanting his mother's love and the mother who just cannot afford to give it because her whole world might fall apart.' Alongside Elliott and Ha, The Survivors also stars Robyn Malcolm, Damien Garvey and Apple Cider Vinegar's Thom Green and Julian Weeks. The full cast is below: The series was filmed throughout the Australian state of Tasmania, and is set in the fictional town of Evelyn Bay, where the book takes place. However, as Ayres stressed in an interview with Netflix, 'Evelyn Bay doesn't actually exist. Jane [Harper] made it up out of a number of different places.' The Survivors was filmed in an area of Tasmania called Eaglehawk Neck, which Ayres noted has 'such a gothic landscape. It's cliffs and sea caves and this pounding ocean. It really is so spectacular.' Netflix has not yet greenlit another season, but given the precedent set by previous the streaming service with its other limited series that it's ended up commissioning second seasons of, including Nobody Wants This and Squid Game, there's still plenty of time for a second outing of The Survivors. The Survivors is available to stream on Netflix now. ELLE Collective is a new community of fashion, beauty and culture lovers. For access to exclusive content, events, inspiring advice from our Editors and industry experts, as well the opportunity to meet designers, thought-leaders and stylists, become a member today HERE. Naomi May is a freelance writer and editor with an emphasis on popular culture, lifestyle and politics. After graduating with a First Class Honours from City University's prestigious Journalism course, Naomi joined the Evening Standard as its Fashion and Beauty Writer, working across both the newspaper and website. She is now the Acting News Editor at ELLE UK and has written features for the likes of The Guardian, Vogue, Vice and Refinery29, among many others.
Yahoo
an hour ago
- Yahoo
Insiders Pull the Trigger on These 2 Market-Beating Stocks
Investors searching for quality stock opportunities often look for reliable signals, and few are as telling as insider activity. Corporate insiders, such as top executives and directors, have an intimate understanding of their company's performance and prospects. When these insiders buy or sell shares, it can offer a powerful glimpse into their confidence – or concern – about what lies ahead. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter To ensure transparency and fairness, federal regulators require insiders to publicly disclose their trades. These filings give everyday investors a unique chance to track where the people closest to the business are putting their money. And when insiders make substantial purchases it's typically because they have strong conviction that the stock is poised to rise. With this in mind, we turned to TipRanks' Insiders' Hot Stocks tool to identify promising names that insiders are actively buying. What we found: two market-beating stocks (both are up over 20% this year), solid upside potential, and recent million-dollar insider purchases. Here's a closer look at the names drawing insider confidence. Starz Entertainment (STRZ) The first stock we'll look at is new to the public trading markets, having gone public through a spinoff transaction that was completed early in May. Lionsgate Entertainment, a long-time stalwart of the film and music industry, split its motion picture and television studio operations and its premium subscription service business ops into two separate entities. The subscription business, Starz, is now trading as an independent company, and debuted on the NASDAQ index on May 7. Starz operates a TV streaming business, offering a variety of popular franchises and series. As a point of differentiation in a crowded industry, Starz bills itself as 'the leading premium entertainment destination for women and underrepresented audiences,' and its programming mix is designed to appeal to a discerning adult audience. Starz prides itself on its programming lineup, which it describes as including 'boundary-breaking' originals as well as blockbuster movies. After going public, Starz released its first set of financial results on May 29. The release covered FQ4 and the full fiscal year that ended this past March 31. For the fourth quarter, Starz reported total revenues of $330.6 million. At the bottom line, the company had a net quarterly operating loss of $136.3 million, and a positive OIBDA (Operating Income Before Depreciation and Amortization) of $93.3 million. Starz's stock has posted sound gains through its first month+ of trading, gaining 58%. But Mark Rachesky of the Board of Directors must sense more gains are on the way. The insider made a major purchase of STRZ stock on June 2, picking up 353,334 shares. This block is currently valued at $5.93 million. For Seaport analyst David Joyce, this newly public stock presents investors with a solid case for buying in. He writes of the shares, 'We believe STRZ has a clear path toward supporting its target demographic subscribers with original content that should support ARPU increases in time, EBITDA growth and margin expansion, FCF conversion, and debt paydown. Longer-term valuations for STRZ could be much higher (and closer to our adjusted blend of peer business mix-weighted multiples), up to $46 and conceivably even ~$56, once sentiment in the sector improves and differentiates among business models…' Joyce sets his initial rating on STRZ at a Buy, with a $30 price target that points toward a one-year gain of 78.5%. (To watch Joyce's track record, click here) Overall, Starz's new stock has earned a Moderate Buy consensus rating based on 3 reviews that include 2 to Buy and 1 to Hold. The shares are currently trading for $16.80 and their $21.33 average target price implies that the stock will gain 27% in the next 12 months. (See STRZ stock forecast) WNS Limited (WNS) The next stock we'll look at is WNS, the eponymous shares of WNS Limited. This firm is a $2.7 billion player in the global business transformation industry, providing the services and savvy in business process management that its clients need to adapt their operations to today's ever-changing environment. WNS is an Indian company on a global scene, with headquarters in Mumbai, London, and New York. The company employs more than 64,000 people in 13 countries around the world, working with more than 700 enterprise clients on 4 continents. This company's clientele is looking for a clear set of services, including digital technology and analytics, as well as AI-powered decision intelligence. WNS provides all of this, and more, assisting its client companies as they upgrade a wide range of business processes in finance and accounting, procurement, HR, research, and data management. The company works with customers in a wide range of industries, including high-tech, shipping and logistics, travel and leisure, utilities and energy, healthcare, insurance, and manufacturing. WNS has been in business since 1996, and has proven itself adaptable to the fast-moving changes of the business world. More recently, the company has added AI services to its line-up, offering its customers access to generative AI tools, in areas from medical summarization to generative AI response interfaces. Year-to-date, WNS shares are up 22%, while the company also beat expectations in its most recent quarterly readout. Those results covered fiscal 4Q25, the quarter ending this past March 31. At the top line, WNS had revenues of $336.3 million, flat year-over-year but some $12.67 million better than had been anticipated. The company's earnings, of $1.45 per share in non-GAAP measures, were 4 cents per share above the forecast. WNS also worked at paying down debt in the quarter; the company reported that it repaid $33 million after generating $53.4 million in cash from operations. At the end of the fiscal year, WNS had $267.4 million in cash and liquid assets on the balance sheet, compared to $243.5 million in debt. Turning to the insiders, we find that WNS's Executive Vice President Anil Chintapalli purchased two blocks of shares this past May, totaling 20,000. At current prices these shares are worth more than $1.19 million. This global company caught the eye of Baird analyst David Koning, who thinks that after a difficult period, the outlook looks upbeat for WNS, while it could also be an attractive takeover target. The 5-star analyst writes of the stock, 'After several one-off headwinds over the past couple years, WNS has returned to normalized sequential growth over the past two quarters. With the likelihood of ongoing normal sequential patterns, we think a return to organic constant-fx yoy growth in the high-single digits is likely by the September 2025 quarter. We think WNS remains an attractive target as (1) BPO (Business Process Outsourcing) has tended to grow faster in recent quarters, (2) BPO has tended to be more stable, (3) we could see cost synergies, (4) valuation is quite attractive relative to history.' At his own bottom line, Koning lays out an optimistic position, saying, 'We like the stock, as we view valuation as reasonable, and consider multiple ways to win…growth accelerates back to ~10%, investors like stable-growth BPO, or the company could sell.' These comments support Koning's Outperform (i.e., Buy) rating, and his $78 price target suggests that WNS will gain 31% over the next year. (To watch Koning's track record, click here) WNS has 6 recent reviews from Wall Street analysts, which break down 5 to 1 in favor of Buy over Hold for a Strong Buy consensus rating. The shares have a current selling price of $59.61 and the $72.20 average target price indicates room for a 21% upside in the next 12 months. (See WNS stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Vermont's Noah Kahan to star in new documentary. What to know
Between headlining a tour, releasing a limited-edition clothing line with L.L. Bean and becoming an investor in Boston Common Golf, the past year has been extremely successful for Vermont singer-songwriter Noah Kahan. However, Kahan isn't done yet. It was recently announced that the Grammy award-winning artist is set to be the subject of a new documentary. According to a press release, the movie will follow Kahan's rise to fame, focusing both on his upbringing in Vermont and important moments in his career. Here's what to know about the Noah Kahan documentary before it drops. Directed by Nick Sweeney and produced by Live Nation Productions, Federal Films, Polygram Entertainment and RadicalMedia, Noah Kahan's documentary will focus on his journey from growing up in Vermont to becoming a worldwide star. According to the press release, the movie will look back over his early career, eventually following him through his 2024 headlining tour, during which he played at Fenway Park. At the end of the movie, fans will get an "intimate look" at Kahan's personal life as he travels back to his home in Vermont following the conclusion of the tour. More: Noah Kahan loved his Fenway concerts so much that he's making them into an album. The documentary will also focus on Kahan's mental health struggles and the pressures of fame. Kahan has always been open with his fans about his mental health, but in his new movie, he will share struggles he hasn't talked about publicly before, per the press release. Currently, there is no release date or title for the documentary. The movie has reportedly completed production and is in the process of finding a distributor. This article originally appeared on Burlington Free Press: Noah Kahan to be subject of new documentary. What to know before it drops
